Early Use of Norepinephrine to Treat Severe Sepsis and Restore Blood Pressure

What this Trial Is About

Sepsis is a serious condition caused by a severe infection leading to widespread inflammation and organ failure. This research evaluates the early use of norepinephrine NE alongside standard treatment to manage low blood pressure and support organ function in patients with severe sepsis. The study aims to determine if starting NE earlier can better restore blood pressure and improve outcomes compared to standard care alone. Participants are randomly assigned to one of two groups. One group receives low-dose norepinephrine infusion early after observing low blood pressure due to sepsis, in addition to usual treatments following the 2021 Surviving Sepsis Campaign guidelines. The other group receives a placebo infusion plus standard therapy. The norepinephrine is given intravenously at a dose adjusted by body weight to maintain target blood pressure. The study monitors treatment over the initial hours and days after sepsis diagnosis. During the study, participants will be closely monitored for blood pressure control within 6 hours, changes in blood lactate levels, the volume of fluids administered within 48 hours, and mortality at 28 days. Researchers will assess organ function and overall response to treatment, following patients throughout their ICU stay and beyond. The trial aims to provide detailed information on the safety and impact of early norepinephrine use in sepsis management.

Early Administration of Norepinephrine in Sepsis